Bronchial epilepsy or broncho-pulmonary hyper-excitability as a model of asthma pathogenesis

Medical Hypotheses

Volumn 67, Issue 5, 2006, Pages 1042-1051

  Hoang, Ba X ^a   Levine, Stephen A ^a   Graeme Shaw, D ^b   Pham, Phuong ^c   Hoang, Cuong ^d  

^a Allergy Research Group   (United States)

^b Advanced Integrative Medicine   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d National Institute of Ophthalmology   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACETYLCHOLINE; ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ESTROGEN; GLUTAMIC ACID; GLYCINE; IRRITANT AGENT; LIDOCAINE; MAGNESIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PROGESTERONE; SODIUM CHANNEL; STEROID;

AIRFLOW; AIRWAY CONSTRICTION; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; BRONCHOSPASM; BRONCHUS; BRONCHUS DISEASE; BRONCHUS EPILEPSY; COUGHING; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SENSITIVITY; DYSPNEA; HEREDITY; HOSPITALIZATION; HUMAN; HYPERVENTILATION; MORBIDITY; NEUROTRANSMISSION; NONHUMAN; PARESTHESIA; PATHOGENESIS; PHARYNX ANESTHESIA; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; RESPIRATORY TRACT INFECTION; SMOOTH MUSCLE; SYMPTOM; THROAT PARESTHESIA; TINNITUS; WHEEZING;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHI; BRONCHIAL HYPERREACTIVITY; CELL MEMBRANE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; HYPERVENTILATION; LIDOCAINE; MALE; MEMBRANE POTENTIALS; MODELS, BIOLOGICAL; NEUROTRANSMITTER AGENTS; PHENYTOIN; RESPIRATION DISORDERS; SODIUM CHANNELS;

EID: 33748138606     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.05.014     Document Type: Article

References (113)

1. Leff A.R. Future directions in asthma therapy. Is a cure possible?. Chest 111 (1997) 61S-68S
2. Leff A.R. Endogenous regulation of bronchomotor tone. Am Rev Respir Dis 137 (1988) 1198-1216
3. Leff A.R. Toward the formulation of a theory of asthma. Perspect Biol Med 33 (1990) 292-302
4. Orange R.P., Austen W.G., and Austen K.F. Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3′,5′-adenosine monophosphate. J Exp Med 134 (1971) 136s-148s
5. Gold W.M. Neurohumoral interactions in airways. Am Rev Respir Dis 115 (1977) 127-137
6. Kaliner M., Orange R.P., and Austen K.F. Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med 136 (1972) 556-567
7. Aizawa T., Sekizawa K., Aikawa T., Maruyama N., Itabashi S., Tamura G., et al. Eosinophil supernatant causes hyperresponsiveness of airway smooth muscle in guinea pig trachea. Am Rev Respir Dis 142 (1990) 133-137
8. Gleich G.J., Flavahan N.A., Fujisawa T., and Vanhoutte P.M. The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J Allergy Clin Immunol 81 (1988) 776-781
9. Hamann K.J., Strek M.E., Baranowski S.L., Munoz N.M., Williams F.S., White S.R., et al. Effects of activated eosinophils cultured from human umbilical cord blood on guinea pig trachealis. Am J Physiol 265 (1993) L301-L307
10. Wenzel S.E., Balzar S., Cundall M., and Chu H.W. Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol 111 (2003) 1345-1352
11. Szczeklik A., and Nizankowska E. Clinical features and diagnosis of aspirin induced asthma. Thorax 55 Suppl 2 (2000) S42-S44
12. Rochat T. Is intrinsic or non-atopic asthma a particular disease?. Rev Med Suisse 1 (2005) 2640-2643
13. Warner J.O. Bronchial hyperresponsiveness, atopy, airway inflammation, and asthma. Pediatr Allergy Immunol 9 (1998) 56-60
14. Gregerson M.B. The curious 2000-year case of asthma. Psychosom Med 62 (2000) 816-827
15. Cavalheiro E.A., and Olney J.W. Glutamate antagonists: deadly liaisons with cancer. Proc Natl Acad Sci USA 98 (2001) 5947-5948
16. Onganer P.U., Seckl M.J., and Djamgoz M.B. Neuronal characteristics of small-cell lung cancer. Br J Cancer 93 (2005) 1197-1201
17. Pancrazio J.J., Viglione M.P., Tabbara I.A., and Kim Y.I. Voltage-dependent ion channels in small-cell lung cancer cells. Cancer Res 49 (1989) 5901-5906
18. Nakashima Y., Sugiyama S., Shindoh J., Taki F., Takagi K., Satake T., et al. Effects of sodium channel blockers on electrical field stimulation-induced guinea-pig tracheal smooth muscle contraction. Arch Int Pharmacodyn Ther 306 (1990) 130-138
19. Stone W.E., and Javid M.J. Anticonvulsive and convulsive effects of lidocaine: comparison with those of phenytoin, and implications for mechanism of action concepts. Neurol Res 10 (1988) 161-168
20. Delgado-Escueta A.V., Wasterlain C., Treiman D.M., and Porter R.J. Current concepts in neurology: management of status epilepticus. N Engl J Med 306 (1982) 1337-1340
21. De Giorgio C.M., Altman K., Hamilton-Byrd E., and Rabinowicz A.L. Lidocaine in refractory status epilepticus: confirmation of efficacy with continuous EEG monitoring. Epilepsia 33 (1992) 913-916
22. Hunt L.W., Swedlund H.A., and Gleich G.J. Effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. Mayo Clin Proc 71 (1996) 361-368
23. Hunt L.W., Frigas E., Butterfield J.H., Kita H., Blomgren J., Dunnette S.L., et al. Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study. J Allergy Clin Immunol 113 (2004) 853-859
24. Decco M.L., Neeno T.A., Hunt L.W., O'Connell E.J., Yunginger J.W., and Sachs M.I. Nebulized lidocaine in the treatment of severe asthma in children: a pilot study. Ann Allergy Asthma Immunol 82 (1999) 29-32
25. Shulman M.H. The use of Dilantin sodium in bronchial asthma: a preliminary report. N Engl J Med 226 (1942) 260-264
26. Sayar B., and Polvan O. Epilepsy and bronchial asthma. Lancet 1 (1968) 1038
27. Shah J.R., Vora G., Karkhanis A.V., and Talwalkar C.V. The effect of diphenylhydantoin on ventilation tests in airway obstruction. Indian J Chest Dis 12 (1970) 10-14
28. Jain S., and Jain K.C. Effect of phenytoin sodium in the management of poorly controlled bronchial asthma at a rural health center in Phalodi, Rajasthan, India. J Asthma 28 (1991) 201-211
29. Olney J.W. Excitotoxic amino acids and neuropsychiatric disorders. Annu Rev Pharmacol Toxicol 30 (1990) 47-71
30. Beal M.F. Mechanisms of excitotoxicity in neurologic diseases. FASEB J 6 (1992) 3338-3344
31. Lipton S.A., and Gendelman H.E. Seminars in medicine of the Beth Israel Hospital, Boston. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 332 (1995) 934-940
32. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16 (1996) 921-932
33. Said S.I., Berisha H.I., and Pakbaz H. Excitotoxicity in the lung: N-methyl-d-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase. Proc Natl Acad Sci USA 93 (1996) 4688-4692
34. Dawson V.L., Dawson T.M., Bartley D.A., Uhl G.R., and Snyder S.H. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci 13 (1993) 2651-2661
35. Haxhiu M.A., Chavez J.C., Pichiule P., Erokwu B., and Dreshaj I.A. The excitatory amino acid glutamate mediates reflexly increased tracheal blood flow and airway submucosal gland secretion. Brain Res 883 (2000) 77-86
36. Said S.I. Glutamate receptors and asthmatic airway disease. Trends Pharmacol Sci 20 (1999) 132-134
37. Dickman K.G., Youssef J.G., Mathew S.M., and Said S.I. Ionotropic glutamate receptors in lungs and airways: molecular basis for glutamate toxicity. Am J Respir Cell Mol Biol 30 (2004) 139-144
38. Allen D.H., Delohery J., and Baker G. Monosodium l-glutamate-induced asthma. J Allergy Clin Immunol 80 (1987) 530-537
39. Said S.I., Berisha H.I., and Pakbaz H. N-methyl-d-aspartate receptors outside the central nervous system: activation causes acute lung injury that is mediated by nitric oxide synthesis and prevented by vasoactive intestinal peptide. Neuroscience 65 (1995) 943-946
40. Shirakawa J., Taniyama K., and Tanaka C. gamma-Aminobutyric acid-induced modulation of acetylcholine release from the guinea pig lung. J Pharmacol Exp Ther 243 (1987) 364-369
41. Chapman R.W., Hey J.A., Rizzo C.A., and Bolser D.C. GABAB receptors in the lung. Trends Pharmacol Sci 14 (1993) 26-29
42. Chapman R.W., Danko G., Rizzo C., Egan R.W., Mauser P.J., and Kreutner W. Prejunctional GABA-B inhibition of cholinergic, neurally-mediated airway contractions in guinea-pigs. Pulm Pharmacol 4 (1991) 218-224
43. Belvisi M.G., Ichinose M., and Barnes P.J. Modulation of non-adrenergic, non-cholinergic neural bronchoconstriction in guinea-pig airways via GABAB-receptors. Br J Pharmacol 97 (1989) 1225-1231
44. Dicpinigaitis P.V., and Dobkin J.B. Antitussive effect of the GABA-agonist baclofen. Chest 111 (1997) 996-999
45. Luzzi S., Franchi-Micheli S., Folco G., Rossoni G., Ciuffi M., and Zilletti L. Effect of baclofen on different models of bronchial hyperreactivity in the guinea-pig. Agents Actions 20 (1987) 307-309
46. Wheeler M., Stachlewitz R.F., Yamashina S., Ikejima K., Morrow A.L., and Thurman R.G. Glycine-gated chloride channels in neutrophils attenuate calcium influx and superoxide production. FASEB J 14 (2000) 476-484
47. Wheeler M.D., Ikejema K., Enomoto N., Stacklewitz R.F., Seabra V., Zhong Z., et al. Glycine: a new anti-inflammatory immunonutrient. Cell Mol Life Sci 56 (1999) 843-856
48. Toth E., and Lajtha A. Glycine potentiates the action of some anticonvulsant drugs in some seizure models. Neurochem Res 9 (1984) 1711-1718
49. Simpson Jr. R.K., Gondo M., Robertson C.S., and Goodman J.C. The influence of glycine and related compounds on spinal cord injury-induced spasticity. Neurochem Res 20 (1995) 1203-1210
50. Simpson Jr. R.K., Robertson C.S., and Goodman J.C. The role of glycine in spinal shock. J Spinal Cord Med 19 (1996) 215-224
51. de Koning T.J., Duran M., Dorland L., Gooskens R., Van Schaftingen E., Jaeken J., et al. Beneficial effects of l-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency. Ann Neurol 44 (1998) 261-265
52. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., and Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56 (1999) 29-36
53. Rose M.L., Cattley R.C., Dunn C., Wong V., Li X., and Thurman R.G. Dietary glycine prevents the development of liver tumors caused by the peroxisome proliferator WY-14,643. Carcinogenesis 20 (1999) 2075-2081
54. Rose M.L., Madren J., Bunzendahl H., and Thurman R.G. Dietary glycine inhibits the growth of B16 melanoma tumors in mice. Carcinogenesis 20 (1999) 793-798
55. Fogarty A., Broadfield E., Lewis S., Lawson N., and Britton J. Amino acids and asthma: a case-control study. Eur Respir J 23 (2004) 565-568
56. Belousov A.B., O'Hara B.F., and Denisova J.V. Acetylcholine becomes the major excitatory neurotransmitter in the hypothalamus in vitro in the absence of glutamate excitation. J Neurosci 21 (2001) 2015-2027
57. Giuliani D., Giaroni C., Zanetti E., Canciani L., Borroni P., Lecchini S., et al. Involvement of glutamate receptors of the NMDA type in the modulation of acetylcholine and glutamate overflow from the guinea pig ileum during in vitro hypoxia and hypoglycaemia. Neurochem Int (2005)
58. Del Castillo J., and Engback L. The nature of the neuromuscular block produced by magnesium. J Physiol 124 (1954) 370-384
59. McLean R.M. Magnesium and its therapeutic uses: a review. Am J Med 96 (1994) 63-76
60. Tence M., Murphy N., Cordier J., Premont J., and Glowinski J. Synergistic effects of acetylcholine and glutamate on the release of arachidonic acid from cultured striatal neurons. J Neurochem 64 (1995) 1605-1613
61. Fu W.M., Liou J.C., Lee Y.H., and Liou H.C. Potentiation of neurotransmitter release by activation of presynaptic glutamate receptors at developing neuromuscular synapses of Xenopus. J Physiol 489 Pt 3 (1995) 813-823
62. Britton J., Pavord I., Richards K., Wisniewski A., Knox A., Lewis S., et al. Dietary magnesium, lung function, wheezing, and airway hyperreactivity in a random adult population sample. Lancet 344 (1994) 357-362
63. Sharma S.K., Bhargava A., and Pande J.N. Effect of parenteral magnesium sulfate on pulmonary functions in bronchial asthma. J Asthma 31 (1994) 109-115
64. Fedoseev G.B., Emel'ianov A.V., Neskoromnyi A.G., Sinitsina T.M., and Emanuel V.L. The role of disorders in the homeostasis of divalent cations in the pathogenesis and clinical picture of bronchial asthma. Ter Arkh 66 (1994) 8-12
65. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1 (1988) 623-634
66. Lipton S.A., and Rosenberg P.A. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330 (1994) 613-622
67. Schiermeyer R.P., and Finkelstein J.A. Rapid infusion of magnesium sulfate obviates need for intubation in status asthmaticus. Am J Emerg Med 12 (1994) 164-166
68. Skorodin M.S., Freebeck P.C., Yetter B., Nelson J.E., Van de Graaff W.B., and Walsh J.M. Magnesium sulfate potentiates several cardiovascular and metabolic actions of terbutaline. Chest 105 (1994) 701-705
69. Hughes R., Goldkorn A., Masoli M., Weatherall M., Burgess C., and Beasley R. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Lancet 361 (2003) 2114-2117
70. Landon R.A., and Young E.A. Role of magnesium in regulation of lung function. J Am Diet Assoc 93 (1993) 674-677
71. Skobeloff E.M., and McNamara R.M. Intravenous magnesium for acute asthma. Ann Emerg Med 22 (1993) 617-618 [author reply 618-9]
72. Khilnani G., Parchani H., and Toshniwal G. Hypomagnesemia due to beta 2-agonist use in bronchial asthma. J Assoc Physicians India 40 (1992) 346
73. Lockhart A. Bronchial provocation tests using hyperventilation. Rev Mal Respir 4 (1987) 217-223
74. Baranes T., Rossignol B., Stheneur C., and Bidat E. Hyperventilation syndrome in children. Arch Pediatr 12 (2005) 1742-1747
75. Martinez-Moragon E., Perpina M., Belloch A., and de Diego A. Prevalence of hyperventilation syndrome in patients treated for asthma in a pulmonology clinic. Arch Bronconeumol 41 (2005) 267-271
76. Seyal M., Mull B., and Gage B. Increased excitability of the human corticospinal system with hyperventilation. Electroencephalogr Clin Neurophysiol 109 (1998) 263-267
77. Vrieze A., Postma D.S., and Kerstjens H.A. Perimenstrual asthma: a syndrome without known cause or cure. J Allergy Clin Immunol 112 (2003) 271-282
78. Gueirreiro C.A., and Ramos M.C. Premenstrual seizure increase: influence of age, duration of disease, seizure frequency, previous complaint of perimenstrual accentuation, EEG and CT scan findings. Arq Neuropsiquiatr 49 (1991) 27-32
79. Barr R.G., Wentowski C.C., Grodstein F., Somers S.C., Stampfer M.J., and Schwartz J. Prospective study of postmenopausal hormone use and newly diagnosed asthma and chronic obstructive pulmonary disease. Arch Intern Med 164 (2004) 379-386
80. Troisi R.J., Speizer F.E., Willett W.C., Trichopoulos D., and Rosner B. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. Am J Respir Crit Care Med 152 (1995) 1183-1188
81. Reddy D.S. Role of neurosteroids in catamenial epilepsy. Epilepsy Res 62 (2004) 99-118
82. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 3 (1990) 588-593
83. Peng B.G., Chen S., and Lin X. Aspirin selectively augmented N-methyl-d-aspartate types of glutamate responses in cultured spiral ganglion neurons of mice. Neurosci Lett 343 (2003) 21-24
84. Wang S.J. Facilitatory effect of aspirin on glutamate release from rat hippocampal nerve terminals: involvement of protein kinase C pathway. Neurochem Int (2005)
85. Steinhauer H.B., and Hertting G. Lowering of the convulsive threshold by non-steroidal anti-inflammatory drugs. Eur J Pharmacol 69 (1981) 199-203
86. Ikonomidou-Turski C., Cavalheiro E.A., Turski L., Bortolotto Z.A., Kleinrok Z., Calderazzo-Filho L.S., et al. Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats. Brain Res 462 (1988) 275-285
87. Najbauer J., Schuman E.M., and Mamelak A.N. The aspirin metabolite sodium salicylate causes focal cerebral hemorrhage and cell death in rats with kainic acid-induced seizures. Neuroscience 99 (2000) 107-117
88. Sanchez-Hernandez M.C., Delgado J., Navarro A.M., Orta J.C., Hernandez M., and Conde J. Seizures induced by NSAID. Allergy 54 (1999) 90-91
89. Zaccara G., Muscas G.C., and Messori A. Clinical features, pathogenesis and management of drug-induced seizures. Drug Saf 5 (1990) 109-151
90. Broide D.H. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 108 (2001) S65-S71
91. Barnes P.J. The role of inflammation and anti-inflammatory medication in asthma. Respir Med 96 Suppl A (2002) S9-S15
92. Bereiter D.A., Okamoto K., Tashiro A., and Hirata H. Endotoxin-induced uveitis causes long-term changes in trigeminal subnucleus caudalis neurons. J Neurophysiol 94 (2005) 3815-3825
93. Xu L., Sun J., Lu R., Ji Q., and Xu J.G. Effect of glutamate on inflammatory responses of intestine and brain after focal cerebral ischemia. World J Gastroenterol 11 (2005) 733-736
94. Oprica M., Eriksson C., and Schultzberg M. Inflammatory mechanisms associated with brain damage induced by kainic acid with special reference to the interleukin-1 system. J Cell Mol Med 7 (2003) 127-140
95. Fairbanks C.A., Schreiber K.L., Brewer K.L., Yu C.G., Stone L.S., Kitto K.F., et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci USA 97 (2000) 10584-10589
96. Levine S., and Kidd P. Antioxidant adaptation (1986), Biocurrents, San-Francisco
97. Newmark T., and Schulick P. Beyond aspirin (2000), Hohm Press, Prescott p. A2
98. ®). Is it safe? (1990), The Charles Press, Philadelphia
99. Lange P., Parner J., Vestbo J., Schnohr P., and Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339 (1998) 1194-1200
100. Peat J.K., Woolcock A.J., and Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 70 (1987) 171-179
101. Sherrill D., Guerra S., Bobadilla A., and Barbee R. The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics. Eur Respir J 21 (2003) 95-100
102. Ulrik C.S., and Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med 150 (1994) 629-634
103. Vonk J.M., Jongepier H., Panhuysen C.I., Schouten J.P., Bleecker E.R., and Postma D.S. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 58 (2003) 322-327
104. Hudon C., Turcotte H., Laviolette M., Carrier G., and Boulet L.P. Characteristics of bronchial asthma with incomplete reversibility of airflow obstruction. Ann Allergy Asthma Immunol 78 (1997) 195-202
105. Reed C.E. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 103 (1999) 539-547
106. Ulrik C.S., and Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 14 (1999) 892-896
107. Alavanja M.C., Brownson R.C., Boice Jr. J.D., and Hock E. Preexisting lung disease and lung cancer among nonsmoking women. Am J Epidemiol 136 (1992) 623-632
108. Brown D.W., Young K.E., Anda R.F., and Giles W.H. Asthma and risk of death from lung cancer: NHANES II mortality study. J Asthma 42 (2005) 597-600
109. Panico L.R., Demartini M.G., Rios V.G., and Carniello M.A. The ketogenic diet in infantile refractory epilepsy: electroclinical response, complications and secondary effects. Rev Neurol 31 (2000) 212-220
110. Freeman J.M., Vining E.P., Pillas D.J., Pyzik P.L., Casey J.C., and Kelly L.M. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics 102 (1998) 1358-1363
111. Schiff Y., and Lerman-Sagie T. Ketogenic diet - an alternative therapy for epilepsy in adults. Harefuah 134 (1998) 529-531 591
112. Kirchner A., Breustedt J., Rosche B., Heinemann U.F., and Schmieden V. Effects of taurine and glycine on epileptiform activity induced by removal of Mg2+ in combined rat entorhinal cortex-hippocampal slices. Epilepsia 44 (2003) 1145-1152
113. Gupta R.C., Win T., and Bittner S. Taurine analogues; a new class of therapeutics: retrospect and prospects. Curr Med Chem 12 (2005) 2021-2039